Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Chau

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Oral Oncology|September 24, 2017
Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapyDanielle N Margalit, Jonathan D Schoenfeld, Bhupendra Rawal, et al.
JCI Insight|February 23, 2018
Frameshift events predict anti-PD-1/L1 response in head and neck cancerGlenn J Hanna, Patrick Lizotte, Megan Cavanaugh, et al.
Cancer Biomarkers : Section a of Disease Markers|April 8, 2017
Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinomaGlenn J Hanna, Vishwajith Sridharan, Danielle N Margalit, et al.
Head & Neck|December 20, 2021
Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomesKevin Tyan, Ji Eun Bae, Jochen H Lorch, et al.
Cancer Immunology Research|June 18, 2016
Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating LymphocytesVishwajith Sridharan, Evisa Gjini, Xiaoyun Liao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2016
Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid TumorsVandana G Abramson, Jeffrey G Supko, Tarah Ballinger, et al.
The Oncologist|April 21, 2020
The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland CancersGlenn J Hanna, Ji Eun Bae, Jochen H Lorch, et al.
British Journal of Cancer|July 6, 2016
Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancerVishwajith Sridharan, Danielle N Margalit, Stephanie A Lynch, et al.
Head & Neck|January 9, 2019
IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparingAnna W LaVigne, Danielle N Margalit, Bhupendra Rawal, et al.
JNCI Cancer Spectrum|April 25, 2020
An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 PatientsNicole G Chau, Clement Ma, Kristina Danga, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Oral Oncology|September 24, 2017
Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapyDanielle N Margalit, Jonathan D Schoenfeld, Bhupendra Rawal, et al.
JCI Insight|February 23, 2018
Frameshift events predict anti-PD-1/L1 response in head and neck cancerGlenn J Hanna, Patrick Lizotte, Megan Cavanaugh, et al.
Cancer Biomarkers : Section a of Disease Markers|April 8, 2017
Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinomaGlenn J Hanna, Vishwajith Sridharan, Danielle N Margalit, et al.
Head & Neck|December 20, 2021
Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomesKevin Tyan, Ji Eun Bae, Jochen H Lorch, et al.
Cancer Immunology Research|June 18, 2016
Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating LymphocytesVishwajith Sridharan, Evisa Gjini, Xiaoyun Liao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2016
Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid TumorsVandana G Abramson, Jeffrey G Supko, Tarah Ballinger, et al.
The Oncologist|April 21, 2020
The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland CancersGlenn J Hanna, Ji Eun Bae, Jochen H Lorch, et al.
British Journal of Cancer|July 6, 2016
Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancerVishwajith Sridharan, Danielle N Margalit, Stephanie A Lynch, et al.
Head & Neck|January 9, 2019
IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparingAnna W LaVigne, Danielle N Margalit, Bhupendra Rawal, et al.
JNCI Cancer Spectrum|April 25, 2020
An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 PatientsNicole G Chau, Clement Ma, Kristina Danga, et al.
Pageof 7